PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Alice Y HoStephen ShiaoSamantha A KobaldJonathan ChenDan G DudaAmy LyVeerle BossuytHae Lin ChoBrittany ArnoldSimon KnottGaorav P GuptaPhilomena McAndrewScott KarlanMourad TighiouartAlona MuzikanskyReva K BashoHeather L McArthurPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Preoperative RT with pembrolizumab is safe and results in high pCR rates and 3-year EFS, despite the lack of pembrolizumab during NAC. PD-L1 and TILs may be predictive biomarkers for preoperative anti-PD1/RT response. Reduction in TILs after adding RT to anti-PD1 highlights the importance of treatment sequencing.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- neoadjuvant chemotherapy
- locally advanced
- radiation therapy
- tyrosine kinase
- patients undergoing
- endothelial cells
- lymph node
- sentinel lymph node
- transcription factor
- rectal cancer
- squamous cell carcinoma
- single cell
- induced pluripotent stem cells
- radiation induced
- early stage
- genome wide analysis